Supplemental Material for: Response to androgen deprivation therapy in a patient with salivary duct carcinoma with an AR W742L mutation: a case report

Androgen receptors (AR) have been identified on majority of SDC patients, which makes it a potential therapeutic target using total androgen blockade (TAB), a treatment option already established for prostate cancer. </p><p dir="ltr">Case Presentation: This report explores a case of a patient who developed SDC post-radiotherapy for Hodgkin Lymphoma.

He showed partial response to TAB before progression of one of the metastatic lesions. Molecular profiling by Guardant360 demonstrated that he had a mutation AR W742L which has been linked to therapeutic resistance in prostate cancer. The patient subsequently developed leptomeningeal disease which is extremely rare, especially secondary to SDC. </p><p dir="ltr">Conclusion: This study highlights a unique mutation AR W742L which has been associated with castration resistance in prostate cancer but little has been published about it in context of SDC.